Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis : results from a phase III international randomized, placebo-controlled trialDUBERTRET, L; STERRY, W; BOS, J. D et al.British journal of dermatology (1951). 2006, Vol 155, Num 1, pp 170-181, issn 0007-0963, 12 p.Article

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyPAPP, K. A; MENTER, A; STROBER, B et al.British journal of dermatology (1951). 2012, Vol 167, Num 3, pp 668-677, issn 0007-0963, 10 p.Article

Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosaceaTAN, J. K. L; GIRARD, C; KROL, A et al.Journal of cutaneous medicine and surgery. 2002, Vol 6, Num 6, pp 529-534, issn 1203-4754, 6 p.Article

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upPAPP, K. A; GRIFFITHS, C. E. M; STROBER, B et al.British journal of dermatology (1951). 2013, Vol 168, Num 4, pp 844-854, issn 0007-0963, 11 p.Article

Systemic gold therapyPAPP, K. A; SHEAR, N. H.Clinics in dermatology. 1991, Vol 9, Num 4, pp 535-551, issn 0738-081XArticle

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsKIMBALL, A. B; GORDON, K. B; FAKHARZADEH, S et al.British journal of dermatology (1951). 2012, Vol 166, Num 4, pp 861-872, issn 0007-0963, 12 p.Article

A global phase III randomized controlled trial of etanercept in psoriasis : safety, efficacy, and effect of dose reductionPAPP, K. A; TYRING, S; LAHFA, M et al.British journal of dermatology (1951). 2005, Vol 152, Num 6, pp 1304-1312, issn 0007-0963, 9 p.Article

The effects of mass and metallicity upon planetary nebula formationPAPP, K. A; PURTON, C. R; KWOK, S. K et al.The Astrophysical journal. 1983, Vol 268, Num 1, pp 145-154, issn 0004-637XArticle

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyPAPP, K. A; LANGLEY, R. G; SIGURGEIRSSON, B et al.British journal of dermatology (1951). 2013, Vol 168, Num 2, pp 412-421, issn 0007-0963, 10 p.Article

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisGOTTLIEB, A. B; LANGLEY, R. G; STROBER, B. E et al.British journal of dermatology (1951). 2012, Vol 167, Num 3, pp 649-657, issn 0007-0963, 9 p.Article

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes : results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisREVICKI, D; WILLIAN, M. K; SAURAT, J.-H et al.British journal of dermatology (1951). 2008, Vol 158, Num 3, pp 549-557, issn 0007-0963, 9 p.Article